EVX B4
Alternative Names: EVX-B4; Group A streptococcal vaccineLatest Information Update: 08 Jul 2025
At a glance
- Originator Evaxion Biotech
- Class Streptococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Streptococcal infections
Most Recent Events
- 25 Jun 2025 EVX B4 is available for licensing as of 25 Jun 2025 https://evaxion.ai/
- 25 Jun 2025 Early research in Streptococcal infections (Prevention) in Denmark (unspecified route) before June 2025
- 25 Jun 2025 Evaxion Biotech plans a preclinical trials in Streptococcus infections (Prevention) in Denmark